Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523858 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
A Phase 3 study of Progressive Multiple Sclerosis (PMS), sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 927
- Enrollment target
- 20
- Study locations
NCT03523858: Active Phase 3 study of Progressive Multiple Sclerosis (PMS), sponsored by Hoffmann-La Roche.
NCT03523858 is a Phase 3 study of Progressive Multiple Sclerosis (PMS) that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 927 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03523858, a Phase 3 study of Progressive Multiple Sclerosis (PMS), is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 927 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
Primary Outcome
NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (confirmed disability progression \[CDP\]; ≥20% increase in timed 25-foot walk test \[T25FWT\]; ≥20% increase in nine-hole peg test \[9HPT\])
Conditions Studied
Interventions
- DRUG Ocrelizumab
Study Locations (20)
California
- MS Center of California - Laguna Hills
- SC3 Research Group, Inc - Pasadena
- University of California San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dragonfly Research, LLC - Wellesley
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic Mellen Center - Cleveland
Texas
- Central Texas Neurology Consultants - Round Rock
- Lone Star Neurology of San Antonio - San Antonio
Other
- University Clinical Center of the Republic of Srpska - Banja Luka
- University Hospital Mostar - Mostar
Connecticut
- Yale University - North Haven
Florida
- University of South Florida - Tampa
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2018-05-28 |
| Est. Completion | 2026-11-12 |
| Phase | Phase 3 |
What the registry record for NCT03523858 still lists
NCT03523858 is an interventional study that assigns participants to a tested intervention. The registered 927 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Progressive Multiple Sclerosis (PMS) appearing as the primary indexed condition, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT03523858 names 20 study sites across 14 states, led by California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT03523858 about?
NCT03523858 is a clinical study titled "A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis". This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
What is the current status of trial NCT03523858?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 927 participants. The study started on 2018-05-28. Estimated completion is 2026-11-12.
What conditions does trial NCT03523858 study?
This clinical trial studies the following conditions: Progressive Multiple Sclerosis (PMS).
What interventions are being tested in trial NCT03523858?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03523858?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03523858 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03523858's enrollment target sits among peer trials
927 339th of 2000 higher than 1,661 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06378541 · 928 participants · NA
Smartphone App Enhanced Facilitation Among Veterans in a Mental Health Inpatient Setting (Project HOPE)
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
- NCT03995082 · 925 participants · NA
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI